Surgical aspects of patients with adenocarcinoma of the stomach operated on for cure
J. A. Soreide, J. A. van Heerden, L. J. Burgart, J. H. Donohue, M. G. Sarr and D. M. Ilstrup
Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minn., USA.
BACKGROUND: A retrospective study was performed to evaluate our recent
results of curative gastric resections for adenocarcinoma. METHODS: Between
1979 and 1988, 187 patients fulfilled study entry criteria. This group of
patients composes 64% of all patients with tumors arising distal to the
gastroesophageal junction. Tumors arising in the region of the
gastroesophageal junction were excluded. Patients were classified according
to the American Society of Anesthesiologists physical status classification
( > or = 3, 56%) and Eastern Cooperative Oncology Group performance
status ( > or = 2, 44%). Histologic characteristics were re-reviewed.
INTERVENTIONS: Subtotal and total gastrectomies were performed in 78% and
22% of the patients, respectively. Extended lymph node dissections were
performed selectively (5%). Adjuvant chemotherapy and radiotherapy were
employed in 3% and 2% of patients, respectively. RESULTS: Postoperative
morbidity and mortality were 27% and 4%, respectively. Synchronous
splenectomy (P = .06) and type of gastric resection (P = .06) showed a
borderline association with postoperative complications, but did not affect
postoperative mortality. With a median follow-up time of 47 months in all
patients, and a median of 9 years in patients still alive, the 5- and
10-year overall survival rates (Kaplan-Meier method) were 48% and 32%,
respectively. In univariate survival analysis, age, American Society of
Anesthesiologists classification, stage, tumor diameter, serosal extension
of tumor lymph node metastases, and type of resection showed prognostic
significance. In the Cox multivariate analysis, however, only serosal
extension of tumor (P < .001) and lymph node metastases (P = .02) were
independent prognostic factors. CONCLUSIONS: Despite the older age and
comorbid conditions of patients with gastric cancer, 5-year survival was
achieved in half the patients by standard radical operations. Until
appropriate controlled prospective studies are performed, total
gastrectomy, splenectomy, and extended lymph node dissection should not be
routinely adopted, given their unproven efficacy and potentially increased
morbidity and mortality.